A research-based, technology-driven Canadian biopharmaceutical company, Bioniche Life Sciences Inc. (TSE: BNC), has recently been granted three new patents for its core proprietary Mycobacterial Cell Wall-DNA Complex (MCC) and the related oligonucleotides.
The patent has composition and methods claims covering the use of hyaluronic acid in combination with the Company's proprietary MCC and oligonucleotide technologies for the treatment of cancer. The patent also covers the use of hyaluronic acid with the anticancer agent tamoxifen for the treatment of cancer.
According to Graeme McRae, President & CEO of Bioniche Life Sciences Inc.:
"Bioniche takes its patent portfolio very seriously. We have more than 300 approved patents or pending patent applications in progress, and we are constantly adding more. This ensures the maximum opportunity for returns on marketed products."
Read the full press release.
Comment Preview